Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been ...

AstraZeneca has set itself the goal of reaching $80 billion in annual revenue by 2030, up from $58.7 billion in 2025. Its oncology business continues to grow, but AstraZeneca is also looking to newer ...

Lonza discusses how navigating shorter DNA-to-IND timelines represents a key milestone in inspiring investor confidence.

Discover how GLP-1 drugs are being studied for potential new indications, from autoimmune diseases and addiction to Parkinson’s and MASH.

Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise.